Charting New Territory by Simulated Modeling of a Clinical Trial

[摘要] Cardiovascular disease (CVD) remains one of the most common comorbidities and causes of death among patients who are treated for ESRD by hemodialysis (1). On the basis of an extensive body of clinical trial evidence, across a spectrum of high CVD risk states from prevalent disease to primary prevention, statin therapy for LDL cholesterol lowering has emerged as one of the most important strategies to reduce risk in populations without ESRD (2–5). By logical extension, two clinical trials to date (Die Deutsche Diabetes Dialyze Studie [4D Study] and A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events [AURORA]) evaluated whether statin therapy was effective for CVD risk reduction in patients with hemodialysis-treated ESRD (6,7). Neither study found a statistically significant benefit on the primary outcomes, whereas some indication of harm related to statin therapy emerged.

[学科分类] 泌尿医学

[关键词] Bone marrow necrosis;Sickle cell disease;Hyperhemolysis syndrome